146 related articles for article (PubMed ID: 29794918)
1. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
[No Abstract] [Full Text] [Related]
2. Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
Beaver JA; Kluetz PG; Pazdur R
N Engl J Med; 2018 Jun; 378(26):2458-2460. PubMed ID: 29949489
[No Abstract] [Full Text] [Related]
3. [New treatment option-apalutamide for nonmetastatic, castration-resistant prostate cancer].
Hadaschik B; Panic A
Urologe A; 2018 Jun; 57(6):729-730. PubMed ID: 29789876
[No Abstract] [Full Text] [Related]
4. Apalutamide shows efficacy in prostate cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
[No Abstract] [Full Text] [Related]
5. Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
Pilon D; Ellis LA; Xiao Y; Behl AS; Lefebvre P
Am J Ther; 2019; 26(3):e422-e424. PubMed ID: 30677005
[No Abstract] [Full Text] [Related]
6. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
Di Nunno V; Santoni M; Massari F
Eur Urol Oncol; 2019 Jul; 2(4):471. PubMed ID: 31277785
[No Abstract] [Full Text] [Related]
7. [Apalutamide for metastatic, castration-sensitive prostate cancer].
Thomas C
Urologe A; 2019 Dec; 58(12):1496-1497. PubMed ID: 31712857
[No Abstract] [Full Text] [Related]
8. Apalutamide: First Global Approval.
Al-Salama ZT
Drugs; 2018 Apr; 78(6):699-705. PubMed ID: 29626324
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide (Erleada) for prostate cancer.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
[No Abstract] [Full Text] [Related]
10. Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.
Bhindi B; Karnes RJ
Eur Urol; 2018 Oct; 74(4):534-535. PubMed ID: 29866462
[No Abstract] [Full Text] [Related]
11. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
12. Loose Regulatory Standards Portend a New Era of Imprecision Oncology.
Khaki AR
Cancer Invest; 2021 Feb; 39(2):120-123. PubMed ID: 33290099
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
14. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
15. [Vorwort].
von Amsberg G; Gschwend JE
Oncol Res Treat; 2020; 43 Suppl 2():5. PubMed ID: 32428911
[No Abstract] [Full Text] [Related]
16. [Progress of the treatment for CRPC].
Ozono S; Furuse H
Nihon Rinsho; 2016 May; 74 Suppl 3():615-8. PubMed ID: 27344804
[No Abstract] [Full Text] [Related]
17. How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.
Moul JW
Can J Urol; 2019 Jun; 26(3):9782-9786. PubMed ID: 31180310
[TBL] [Abstract][Full Text] [Related]
18. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
19. [A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].
Rexer H; Hammerer P
Urologe A; 2016 Mar; 55(3):395-7. PubMed ID: 26820656
[No Abstract] [Full Text] [Related]
20. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
